Biotinylated Human CD4, His Tag (CD4-H82E8) is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Pro 396 (Accession # P01730-1).
Predicted N-terminus: Lys 26
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 45.0 kDa. The protein migrates as 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human CD4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized HIV GP120 (HIV), His Tag (Cat. No. GP5-V15224) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD4, His Tag, Avi Tag (Cat. No. CD4-H82E8) with a linear range of 2-39 ng/mL (QC tested).
Immobilized HIV GP120 (HIV), His Tag (Cat. No. GP4-V15223) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD4, His Tag, Avi Tag (Cat. No. CD4-H82E8) with a linear range of 2-78 ng/mL (QC tested).
T-cell surface glycoprotein CD4 is also known as T-cell surface antigen T4/Leu-3. CD4 contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CD4 is accessory protein for MHC class-II antigen/T-cell receptor interaction. CD4 induces the aggregation of lipid rafts. CD4 is a primary receptor used by HIV-1 to gain entry into host T cells. HIV infection leads to a progressive reduction of the number of T cells possessing CD4 receptors. Therefore, medical professionals refer to the CD4 count to decide when to begin treatment for HIV-infected patients.
- (1) Brady RL, et al., 1993, Science 260 (5110): 979–83.
- (2) Zeitlmann, L., et al., 2001, J. Biol. Chem. (United States) 276 (12): 9123–32.
- (3) Rudd CE, et al., 2010, J. Immunol. 185 (5): 2645–9.
- (4) Rudd CE, et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85 (14): 5190–4.
- (5) Gorska MM, et al., 2004, J. Exp. Med. 199 (3): 369–79.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
专利使用说明（Limited Use License）
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrobiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.